Living Cell Technologies closes IPO
Friday, 27 August, 2004
Living Cell Technologies has closed its IPO after raising AUD$6.36 million from institutional and retail clients of underwriting stockbroker Taylor Collinson.
The company is expected to move from the Newcastle stock exchange (NSX) to the ASX on September 1, and has been suspended from trading on the NSX in preparation.
"LCT is a unique biotechnology company with an international infrastructure, significant scientific and commercial potential and a clear path to market. Transferring to the ASX is a significant and strategic step in our development and the keen interest in our capital raising not only validates our hard work to date but will underscore continued success in further developing our unique technology," said CEO David Collinson in a statement.
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
Archer completes potassium sensing alpha prototype
Quantum technology company Archer Materials Limited has developed an early Biochip prototype...
